Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement

Creative Commons License

YALÇIN Ş., Trad D., Kader Y. A., Halawani H., Demir O. G., Mall R., ...Daha Fazla

FUTURE ONCOLOGY, cilt.10, sa.16, ss.2643-2657, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 10 Sayı: 16
  • Basım Tarihi: 2014
  • Doi Numarası: 10.2217/fon.14.203
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2643-2657
  • Hacettepe Üniversitesi Adresli: Evet

Özet

The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). Increasingly combination chemotherapy, with or without a targeted agent, is being used to facilitate curative liver resection and improve survival rates in patients with initially unresectable but potentially resectable mCRC. Currently, the only selective marker for the treatment of patients with mCRC is tumor RAS mutational status. BRAF status is a strong prognostic indicator. Medical and clinical oncologists from Central Asia, Russia, the Middle East, Africa and Turkey reviewed data for the use of targeted agents in the treatment of patients with mCRC and have formed recommendations for the biological of choice first-line for patients with mCRC.